Convergent dysbiosis of gastric mucosa and fluid microbiome during stomach carcinogenesis Cong HeChao PengNonghua Lu Original Article 04 June 2022 Pages: 837 - 849
Lipocalin-2 negatively regulates epithelial–mesenchymal transition through matrix metalloprotease-2 downregulation in gastric cancer Sadaaki NishimuraYurie YamamotoMasakazu Yashiro Original Article Open access 15 June 2022 Pages: 850 - 861
Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model Kyoko YamaguchiTomoyasu YoshihiroEishi Baba Original Article 04 June 2022 Pages: 862 - 878
Centromeric protein K (CENPK) promotes gastric cancer proliferation and migration via interacting with XRCC5 Hongwei TianFang WangTiankang Guo Original Article 17 June 2022 Pages: 879 - 895
Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy Yu YangYoshimasa AkashiTatsuya Oda Original Article 17 June 2022 Pages: 896 - 905
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer Merel J. M. van VelzenAafke CreemersHanneke W. M. van Laarhoven Original Article Open access 28 June 2022 Pages: 906 - 915
Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis Taro IwatsuboToshihisa TakeuchiKazuhide Higuchi Original Article 27 May 2022 Pages: 916 - 926
Correction to: Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis Taro IwatsuboToshihisa TakeuchiKazuhide Higuchi Correction 30 July 2022 Pages: 927 - 928
Risk factors for the failure of endoscopic resection of gastric submucosal tumors: a long-term retrospective case–control study Yuzhu YuanLixin SunChunhua Jiao Original Article 26 June 2022 Pages: 929 - 942
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma Zhihao LuSilu YangLin Shen Original Article Open access 02 July 2022 Pages: 943 - 955
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world Toshirou NishidaShinsuke SatoThe STAR ReGISTry Investigators Original Article 07 June 2022 Pages: 956 - 965
Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction Takuro SaitoYukinori KurokawaYuichiro Doki Original Article 30 April 2022 Pages: 966 - 972
Minimum resection length to ensure a pathologically negative distal margin and the preservation of a larger remnant stomach in proximal gastrectomy for early upper gastric cancer Yasufumi KoterazawaManabu OhashiSouya Nunobe Original Article 26 May 2022 Pages: 973 - 981
Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis Giulia GrizziFausto PetrelliAndrea Celotti Short Communication 15 June 2022 Pages: 982 - 987